Search

Your search keyword '"Den braber-Moerland, Leontien"' showing total 3 results
Start Over Author "Den braber-Moerland, Leontien" Database OAIster
3 results on '"Den braber-Moerland, Leontien"'

1. Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis

Author

Hughes, Jordana, Jokubaitis, Vilija, Lugaresi, Alessandra, Hupperts, Raymond, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ramo-Tello, Cristina, Trojano, Maria, Slee, Mark, Shaygannejad, Vahid, Boz, Cavit, Lechner-Scott, Jeanette, Van Pesch, Vincent, Pucci, Eugenio, Solaro, Claudio, Verheul, Freek, Terzi, Murat, Granella, Franco, Spitaleri, Daniele, Alroughani, Raed, Jun, Jae-Kwan, Fambiatos, Adam, Van Der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas, De Luca, Giovanna, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, Di Ioia, Maria, Farina, Deborah, Mancinelli, Luca, Vitetta, Francesca, Simone, Anna Maria, Haartsen, Jodi, Spelman, Tim, Marriott, Mark, Kilpatrick, Trevor, King, John, Buzzard, Katherine, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Brown, J William L, Kunchok, Amy, Diamanti, Matteo, Cartechini, Elisabetta, Curti, Erica, Tsantes, Elena, Zwanikken, Cees, Rio, Maria Edite, Hughes, Stella, Amato, Maria Pita, Van Wijmeersch, Bart, Sanchez-Menoyo, Jose Luis, Bolaños, Ricardo Fernandez, Sajedi, Seyed Aidin, Iuliano, Gerardo, Den Braber-Moerland, Leontien, Prevost, Julie, Sempere, Angel Perez, Sidhom, Youssef, Butler, Ernest, Vucic, Steve, Taylor, Bruce, Cabrera-Gomez, Jose Antonio, Oreja-Guevara, Celia, Bergamaschi, Roberto, Turkoglu, Recai, Olascoaga, Javier, Cristiano, Edgardo, Rojas, Juan Ingacio, Hodgkinson, Suzanne, Skibina, Olga, Al-Harbi, Talal, Altintas, Ayse, McCombe, Pamela, Sinnige, LGF, Ozakbas, Serken, Saladino, Maria Laura, Bacile, Elizabeth Alejandra, Vrech, Carlos, Shaw, Cameron, Hughes, Jordana, Jokubaitis, Vilija, Lugaresi, Alessandra, Hupperts, Raymond, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ramo-Tello, Cristina, Trojano, Maria, Slee, Mark, Shaygannejad, Vahid, Boz, Cavit, Lechner-Scott, Jeanette, Van Pesch, Vincent, Pucci, Eugenio, Solaro, Claudio, Verheul, Freek, Terzi, Murat, Granella, Franco, Spitaleri, Daniele, Alroughani, Raed, Jun, Jae-Kwan, Fambiatos, Adam, Van Der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas, De Luca, Giovanna, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, Di Ioia, Maria, Farina, Deborah, Mancinelli, Luca, Vitetta, Francesca, Simone, Anna Maria, Haartsen, Jodi, Spelman, Tim, Marriott, Mark, Kilpatrick, Trevor, King, John, Buzzard, Katherine, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Brown, J William L, Kunchok, Amy, Diamanti, Matteo, Cartechini, Elisabetta, Curti, Erica, Tsantes, Elena, Zwanikken, Cees, Rio, Maria Edite, Hughes, Stella, Amato, Maria Pita, Van Wijmeersch, Bart, Sanchez-Menoyo, Jose Luis, Bolaños, Ricardo Fernandez, Sajedi, Seyed Aidin, Iuliano, Gerardo, Den Braber-Moerland, Leontien, Prevost, Julie, Sempere, Angel Perez, Sidhom, Youssef, Butler, Ernest, Vucic, Steve, Taylor, Bruce, Cabrera-Gomez, Jose Antonio, Oreja-Guevara, Celia, Bergamaschi, Roberto, Turkoglu, Recai, Olascoaga, Javier, Cristiano, Edgardo, Rojas, Juan Ingacio, Hodgkinson, Suzanne, Skibina, Olga, Al-Harbi, Talal, Altintas, Ayse, McCombe, Pamela, Sinnige, LGF, Ozakbas, Serken, Saladino, Maria Laura, Bacile, Elizabeth Alejandra, Vrech, Carlos, and Shaw, Cameron

Published
2018

2. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent

Author

UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Spelman, Tim, Gray, Orla, Trojano, Maria, Petersen, Thor, Izquierdo, Guillermo, Lugaresi, Alessandra, Hupperts, Raymond, Bergamaschi, Roberto, Duquette, Pierre, Grammond, Pierre, Giuliani, Giorgio, Boz, Cavit, Verheul, Freek, Oreja-Guevara, Celia, Barnett, Michael, Grand'Maison, Francois, Edite Rio, Maria, Lechner-Scott, Jeannette, Van Pesch, Vincent, Fernandez Bolanos, Ricardo, Flechter, Shlomo, Den Braber-Moerland, Leontien, Iuliano, Gerardo, Amato, Maria Pia, Slee, Mark, Cristiano, Edgardo, Saladino, Maria Laura, Paine, Mark, Vella, Norbert, Kasa, Krisztian, Deri, Norma, Herbert, Joseph, Moore, Fraser, Petkovska-Boskova, Tatjana, Alroughani, Raed, Savino, Aldo, Shaw, Cameron, Vucic, Steve, Santiago, Vetere, Bacile, Elizabeth Alejandra, Skromne, Eli, Poehlau, Dieter, Cabrera-Gomez, Jose Antonio, Lucas, Robyn, Butzkueven, Helmut, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Spelman, Tim, Gray, Orla, Trojano, Maria, Petersen, Thor, Izquierdo, Guillermo, Lugaresi, Alessandra, Hupperts, Raymond, Bergamaschi, Roberto, Duquette, Pierre, Grammond, Pierre, Giuliani, Giorgio, Boz, Cavit, Verheul, Freek, Oreja-Guevara, Celia, Barnett, Michael, Grand'Maison, Francois, Edite Rio, Maria, Lechner-Scott, Jeannette, Van Pesch, Vincent, Fernandez Bolanos, Ricardo, Flechter, Shlomo, Den Braber-Moerland, Leontien, Iuliano, Gerardo, Amato, Maria Pia, Slee, Mark, Cristiano, Edgardo, Saladino, Maria Laura, Paine, Mark, Vella, Norbert, Kasa, Krisztian, Deri, Norma, Herbert, Joseph, Moore, Fraser, Petkovska-Boskova, Tatjana, Alroughani, Raed, Savino, Aldo, Shaw, Cameron, Vucic, Steve, Santiago, Vetere, Bacile, Elizabeth Alejandra, Skromne, Eli, Poehlau, Dieter, Cabrera-Gomez, Jose Antonio, Lucas, Robyn, and Butzkueven, Helmut

Abstract

OBJECTIVE: Previous studies assessing seasonal variation of relapse onset in multiple sclerosis have had conflicting results. Small relapse numbers, differing diagnostic criteria, and single region studies limit the generalizability of prior results. The aim of this study was to determine whether there is a temporal variation in onset of relapses in both hemispheres and to determine whether seasonal peak relapse probability varies with latitude. METHODS: The international MSBase Registry was utilized to analyze seasonal relapse onset distribution by hemisphere and latitudinal location. All analyses were weighted for the patient number contributed by each center. A sine regression model was used to model relapse onset and ultraviolet radiation (UVR) seasonality. Linear regression was used to investigate associations of latitude and lag between UVR trough and subsequent relapse peak. RESULTS: A total of 32,762 relapses from 9,811 patients across 30 countries were analyzed. Relapse onset followed an annual cyclical sinusoidal pattern with peaks in early spring and troughs in autumn in both hemispheres. Every 10° of latitude away from the equator was associated with a mean decrease in UVR trough to subsequent relapse peak lag of 28.5 days (95% confidence interval = 3.29-53.71, p = 0.028). INTERPRETATION: We demonstrate for the first time that there is a latitude-dependent relationship between seasonal UVR trough and relapse onset probability peak independent of location-specific UVR levels, with more distal latitude associated with shorter gaps. We confirm prior meta-analyses showing a strong seasonal relapse onset probability variation in the northern hemisphere, and extend this observation to the southern hemisphere. Ann Neurol 2014;76:880-890.

Published
2014

3. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

Author

Kalincik, Tomas, Spelman, Timothy, Trojano, Maria, Duquette, Pierre, Izquierdo, Guillermo, Grammond, Pierre, Lugaresi, Alessandra, Hupperts, Raymond, Cristiano, Edgardo, Van Pesch, Vincent, Grand'Maison, Francois, La Spitaleri, Daniele, Rio, Maria Edite, Flechter, Shlomo, Oreja-Guevara, Celia, Giuliani, Giorgio, Savino, Aldo, Amato, Maria Pia, Peterson, Thor, Fernandez-Bolanos, Ricardo, Bergamaschi, Roberto, Iuliano, Gerardo, Boz, Cavit, Lechner-Scott, Jeannette, Deri, Norma, Gray, Orla, Verheul, Freek, Fiol, Marcela, Barnett, Michael, van Munster, Erik, Santiago, Vetere, Moore, Fraser, Slee, Mark, Saladino, Maria Laura, Alroughani, Raed, Shaw, Cameron, Kasa, Krisztian, Petkovska-Boskova, Tatjana, den Braber-Moerland, Leontien, Chapman, Joab, Skromne, Eli, Herbert, Joseph, Peohlau, Dieter, Needham, Merrilee, Bacile, Elizabeth Alejandra, Oleschko Arruda, Walter, Paine, Mark, Singhal, Bhim, Vucic, Steve, Cabrera-Gomez, Jose Antonio, Butkueven, Helmut, Kalincik, Tomas, Spelman, Timothy, Trojano, Maria, Duquette, Pierre, Izquierdo, Guillermo, Grammond, Pierre, Lugaresi, Alessandra, Hupperts, Raymond, Cristiano, Edgardo, Van Pesch, Vincent, Grand'Maison, Francois, La Spitaleri, Daniele, Rio, Maria Edite, Flechter, Shlomo, Oreja-Guevara, Celia, Giuliani, Giorgio, Savino, Aldo, Amato, Maria Pia, Peterson, Thor, Fernandez-Bolanos, Ricardo, Bergamaschi, Roberto, Iuliano, Gerardo, Boz, Cavit, Lechner-Scott, Jeannette, Deri, Norma, Gray, Orla, Verheul, Freek, Fiol, Marcela, Barnett, Michael, van Munster, Erik, Santiago, Vetere, Moore, Fraser, Slee, Mark, Saladino, Maria Laura, Alroughani, Raed, Shaw, Cameron, Kasa, Krisztian, Petkovska-Boskova, Tatjana, den Braber-Moerland, Leontien, Chapman, Joab, Skromne, Eli, Herbert, Joseph, Peohlau, Dieter, Needham, Merrilee, Bacile, Elizabeth Alejandra, Oleschko Arruda, Walter, Paine, Mark, Singhal, Bhim, Vucic, Steve, Cabrera-Gomez, Jose Antonio, and Butkueven, Helmut

Abstract

To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon β-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon β-1a in either dosage (22 µg or 44 µg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded. Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as “lack of efficacy” (3.3% vs. 1.7%), “scheduled stop” (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 µg vs. 44 µg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages. Treatment discontinuations were more common in interferon β-1a 22 µg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from &ldquo

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results